Synthetic educational example. Do not self-treat: a qualified treating physician must verify the sources, patient data, contraindications, and final plan.
Patient
VERIFIED-AML-L2-AML_2L_KMT2A_REVUMENIB · Algorithm: ALGO-AML-2L
Clinical significance of mutations (ESCAT)
Tumor-board context — the engine does not use these tiers to rank tracks
| Biomarker | Variant | ESCAT | Evidence | Clinical significance | Drugs | Sources |
|---|
| No clinically actionable variants matched in this profile. |
Primary current-line option
- Indication
- IND-AML-2L-KMT2A-REVUMENIB
- Regimen
- Revumenib monotherapy for R/R KMT2A-rearranged AML
- Drugs + NSZU
- Revumenib (DRUG-REVUMENIB) 163 mg PO q12h with strong CYP3A inhibitor (cobicistat) co-administration; OR 270 mg PO q12h without CYP3A inhibitor · continuous, 28-day cycles, until progression / unacceptable toxicity / proceed to alloHCT in CR · PO ✗ Not registered in UA
- Supportive care
- SUP-PJP-PROPHYLAXIS, SUP-HSV-PROPHYLAXIS, SUP-HBV-PROPHYLAXIS
- Reason
- Primary current-line option selected by ALGO-AML-2L at step 6b; branch-driving red flag: RF-AML-KMT2A-ACTIONABLE.
Other current-line alternatives (3 tracks)
Same treatment line; review when biomarker, access, contraindication, or patient-context assumptions change.
- Indication
- IND-AML-2L-GILTERITINIB-FLT3
- Regimen
- Gilteritinib monotherapy for R/R FLT3-mutated AML
- Drugs + NSZU
- Gilteritinib (DRUG-GILTERITINIB) 120 mg PO once daily · continuous, 28-day cycles, until progression / unacceptable toxicity · PO ✗ Not registered in UA
- Supportive care
- SUP-PJP-PROPHYLAXIS, SUP-HSV-PROPHYLAXIS, SUP-HBV-PROPHYLAXIS
- Reason
- Current-line alternative presented for HCP consideration
- Indication
- IND-AML-2L-IDH2-ENASIDENIB
- Regimen
- Enasidenib monotherapy for R/R IDH2-mutated AML
- Drugs + NSZU
- Enasidenib (DRUG-ENASIDENIB) 100 mg PO once daily · continuous, 28-day cycles, until progression / unacceptable toxicity · PO ✗ Not registered in UA
- Supportive care
- SUP-PJP-PROPHYLAXIS, SUP-HSV-PROPHYLAXIS, SUP-HBV-PROPHYLAXIS
- Reason
- Current-line alternative presented for HCP consideration
- Indication
- IND-AML-1L-VEN-AZA
- Regimen
- Venetoclax + Azacitidine (AML, unfit) — VIALE-A schedule
- Drugs + NSZU
- Venetoclax (DRUG-VENETOCLAX) Cycle 1 ramp: day 1 = 100 mg, day 2 = 200 mg, day 3 = 400 mg → days 4-28 = 400 mg PO daily; subsequent cycles = 400 mg daily continuously · PO daily; reduce to ~70-100 mg if combined with strong CYP3A4 inhibitor (posaconazole) · PO ⚠ NSZU — not for this indication
- Azacitidine (DRUG-AZACITIDINE) 75 mg/m²/day · SC or IV days 1-7 of each 28-day cycle · SC ⚠ NSZU — not for this indication
- Supportive care
- SUP-TLS-PROPHYLAXIS, SUP-PJP-PROPHYLAXIS, SUP-HSV-PROPHYLAXIS, SUP-HBV-PROPHYLAXIS
- Reason
- Current-line alternative presented for HCP consideration
Why this branch was chosen
Triggers from the patient profile that fired and drove the chosen branch.
Step 6b → branch IND-AML-2L-KMT2A-REVUMENIB
- RF-AML-KMT2A-ACTIONABLE ★ winner: KMT2A rearrangement (MLL fusion at 11q23) in AML — ~5-10% prevalence in adult AML; ELN-2022 adverse-risk classifier. Revumenib (menin inhibitor; AUGMENT-101 phase 1/2) FDA-approved Nov 2024 for relapsed/ refractory KMT2A-rearranged acute leukemia after ≥1 prior line (ORR ~63%, CR/CRh ~23%). Ziftomenib alternative menin inhibitor in late-phase trials. Common partners: AF9 (t(9;11)) and AF4 (t(4;11)).
SRC-NCCN-AML-2025SRC-ELN-AML-2022
Pre-treatment investigations
Investigations before treatment start · critical / standard / desired · merged across tracks
| ID | Name | Priority | Category | Where to order | Needed for |
|---|
| TEST-BM-ASPIRATE | Bone Marrow Aspirate | Critical | histology | — | all tracks |
| TEST-BM-TREPHINE | Bone Marrow Trephine | Critical | histology | — | all tracks |
| TEST-CBC | Complete Blood Count with Differential | Critical | lab | — | all tracks |
| TEST-CMP | Comprehensive Metabolic Panel | Critical | lab | — | all tracks |
| TEST-COAG-PANEL | Coagulation Panel | Critical | lab | — | all tracks |
| TEST-FISH-PANEL | FISH (Fluorescence In Situ Hybridization) | Critical | genomic | CSD Lab ✓ (code TBC) | all tracks |
| TEST-FLOW-CYTOMETRY | Flow Cytometry | Critical | histology | CSD Lab ✓ (code TBC) | all tracks |
| TEST-HBV-SEROLOGY | Hepatitis B Serology Panel (HBsAg, anti-HBc total, anti-HBs) | Critical | lab | — | all tracks |
| TEST-HCV-ANTIBODY | HCV Antibody | Critical | lab | — | all tracks |
| TEST-HIV-SEROLOGY | HIV Antibody/Antigen | Critical | lab | — | all tracks |
| TEST-KARYOTYPE | Karyotype | Critical | genomic | CSD Lab ✓ (code TBC) | all tracks |
| TEST-LDH | Lactate Dehydrogenase | Critical | lab | — | all tracks |
| TEST-LFT | Liver Function Tests (ALT, AST, bilirubin, ALP, GGT, albumin) | Critical | lab | — | all tracks |
| TEST-NGS-MYELOID-PANEL | Myeloid NGS Panel | Critical | genomic | CSD Lab ✓ (code TBC) | all tracks |
| TEST-PERIPHERAL-SMEAR | Peripheral Blood Smear | Critical | lab | CSD Lab ✓ (code TBC) | standard |
| TEST-ECHO | Echocardiography | Standard | imaging | — | aggressive |
| TEST-URIC-ACID | Serum Uric Acid | Standard | lab | — | all tracks |
Red flags — PRO / CONTRA aggressive
PRO-AGGRESSIVE
Triggers that push toward the aggressive track
- AML emergency triad: hyperleukocytosis (WBC ≥100 K/μL), tumor lysis syndrome (LDH >2× ULN, uric acid >7.5 mg/dL, K+ rising, phosphate rising, Ca2+ falling), or symptomatic leukostasis (dyspnea, altered mental status, retinal hemorrhage)
Triggers HOLD on regimen selection until emergency stabilization: cytoreduction with hydroxyurea ± leukapheresis, IV hydration + rasburicase / allopurinol for TLS, electrolyte correction, urgent ICU/heme consult. Plan generation does not…
RF-AML-EMERGENCY-TLS-LEUKOSTASISSRC-NCCN-AML-2025SRC-ELN-AML-2022SRC-ESMO-AML-2020 - AML with FLT3-ITD or FLT3-TKD mutation — addition of midostaurin (or gilteritinib in r/r) to induction is required (RATIFY trial)
Triggers addition of midostaurin 50 mg PO BID days 8-21 to 7+3 induction + HiDAC consolidation in fit patients. Gilteritinib is the r/r-AML standard. NOT applicable for unfit patients on ven+aza (FLT3-targeting in that setting under…
RF-AML-FLT3-ACTIONABLESRC-NCCN-AML-2025SRC-RATIFY-STONE-2017SRC-ELN-AML-2022 - IDH2 R140Q or R172K activating mutation in AML — ~8-12% prevalence. Enasidenib (IDHIFA / IDHENTIFY — phase-3 R/R AML; monotherapy ORR 38%, CR 19%) is FDA-approved for R/R-AML-IDH2; also active 1L combination with azacitidine in unfit (AG221-AML-005 — ORR 71%).
Detection: NGS panel (no IDH2-specific IHC widely deployed). Differentiation syndrome on enasidenib (~14%) — same monitoring + dexamethasone protocol as ivosidenib. Hyperbilirubinemia on enasidenib (~80% any grade; UGT1A1 inhibition —…
RF-AML-IDH2-MUT-ACTIONABLESRC-NCCN-AML-2025SRC-ELN-AML-2022SRC-ESMO-AML-2020 - AML patient with positive HBV / HCV / HIV serology, latent TB, or active uncontrolled infection — needs antiviral prophylaxis (HBV-active prophylaxis with entecavir/tenofovir; HCV expert consult; ART optimization for HIV; TB treatment) before induction
Direction "hold" surfaces a workup-prerequisite annotation. AML induction (anthracycline + cytarabine) and ven+aza both cause profound immunosuppression with high HBV-reactivation risk if HBsAg+ or anti-HBc+ without prophylaxis. HBV…
RF-AML-INFECTION-SCREENINGSRC-NCCN-AML-2025SRC-ELN-AML-2022 - KMT2A rearrangement (MLL fusion at 11q23) in AML — ~5-10% prevalence in adult AML; ELN-2022 adverse-risk classifier. Revumenib (menin inhibitor; AUGMENT-101 phase 1/2) FDA-approved Nov 2024 for relapsed/ refractory KMT2A-rearranged acute leukemia after ≥1 prior line (ORR ~63%, CR/CRh ~23%). Ziftomenib alternative menin inhibitor in late-phase trials. Common partners: AF9 (t(9;11)) and AF4 (t(4;11)).
Detection: karyotype + FISH break-apart probe at diagnosis; RT-PCR or RNA-NGS for fusion partner identification. Differentiation syndrome on revumenib (~16%) — monitor for fever, dyspnea, weight gain, effusions; treat with dexamethasone +…
RF-AML-KMT2A-ACTIONABLESRC-NCCN-AML-2025SRC-ELN-AML-2022
CONTRA-AGGRESSIVE
Hard contraindications to escalation
What NOT to do
Explicit prohibitive rules, each grounded in a regimen / supportive care / contraindication entity
Aggressive plan (IND-AML-2L-KMT2A-REVUMENIB)
- Do NOT prescribe without confirmation of KMT2A rearrangement at the time of relapse — karyotype + FISH break-apart mandatory.
- Do NOT skip baseline + serial ECG + electrolyte correction (K+ ≥4.0, Mg++ ≥2.0) — QTc prolongation documented.
- Do NOT ignore differentiation syndrome (fever, dyspnea, weight gain, pleural effusion, leukocytosis) — fatal without dexamethasone + cytoreduction.
- Do NOT consider as curative monotherapy — bridging to alloHSCT is mandatory for fit responders.
- Do NOT combine with strong CYP3A4 inducers — substantial reduction in exposure; avoid.
- Do NOT confirm the plan without funding pathway — drug not registered in Ukraine (Syndax EAP / cross-border only).
Aggressive plan (IND-AML-2L-GILTERITINIB-FLT3)
- Do NOT prescribe without re-testing FLT3 at the time of relapse — FLT3 clone can disappear or evolve; ~25% relapse-loss FLT3.
- Do NOT skip baseline + serial ECG + electrolyte correction (K+ ≥4.0, Mg++ ≥2.0) — torsades documented.
- Do NOT ignore differentiation syndrome (fever, dyspnea, weight gain, pleural effusion) — fatal without dexamethasone.
- Do NOT consider as curative monotherapy — bridging to alloHCT is mandatory for fit responders.
- Do NOT combine with strong CYP3A4-inhibitors without dose reduction + intensive QTc monitoring.
- Do NOT discontinue on transient cytopenia — recovery is often slow; G-CSF + transfusion support as needed.
- Do NOT confirm the plan without funding pathway — drug not registered in Ukraine.
Aggressive plan (IND-AML-2L-IDH2-ENASIDENIB)
- Do NOT prescribe without confirmation of IDH2 R140Q or R172K mutation (NGS panel) — enasidenib is not active in IDH2-WT.
- Do NOT skip differentiation syndrome education + corticosteroid kit — fatal without immediate dexamethasone.
- Do NOT declare non-response earlier than 6 cycles — median time to first response ~1.9 months; slow kinetics.
- Do NOT automatically reduce dose for hyperbilirubinemia — if asymptomatic (UGT1A1 inhibition), continue without change.
- Do NOT consider as curative monotherapy — bridging to alloHSCT is mandatory for fit responders.
- Do NOT combine with strong CYP3A4 inducers without monitoring — reduced exposure.
- Do NOT confirm the plan without funding pathway — drug not registered in Ukraine; EU CHMP negative.
Standard plan (IND-AML-1L-VEN-AZA)
- Do not skip the 3-day venetoclax ramp + TLS prophylaxis — fatal TLS cases described when skipping the ramp.
- Do not use full-dose venetoclax (400 mg) with a strong CYP3A4 inhibitor (azole) — reduction to ~70-100 mg required.
- Do not skip HBV screening + prophylaxis — reactivation on HMA + venetoclax described.
- Do not expect a rapid response — azacitidine requires 4-6 cycles; do not stop earlier without progression.
- Do not skip G-CSF in febrile neutropenia — cumulative cytopenias expected; antimicrobial prophylaxis is mandatory.
Timeline
Treatment timeline — derived from regimen + monitoring schedule
Aggressive plan
Induction · Revumenib monotherapy for R/R KMT2A-rearranged AML
28-day cycles × Continuous until progression / unacceptable toxicity; proceed to alloHCT in fit responders
Aggressive plan
Induction · Gilteritinib monotherapy for R/R FLT3-mutated AML
28-day cycles × Continuous until progression / unacceptable toxicity / proceed to alloHCT in CR
Aggressive plan
Induction · Enasidenib monotherapy for R/R IDH2-mutated AML
28-day cycles × Continuous until progression / unacceptable toxicity; proceed to alloHCT in fit responders. Continue ≥6 cycles before declaring non-response (median time to first response ~1.9 mo).
Standard plan
Induction · Venetoclax + Azacitidine (AML, unfit) — VIALE-A schedule
28-day cycles × Continue until progression / unacceptable toxicity (median ~12 cycles in VIALE-A; ~25-30% achieve durable remission)
MDT brief
Discussion questions (1, 0 blocking)
MDT talk tree (2 steps)
| # | Owner | Topic | Action |
|---|
| 1 | hematologist | Staging / disease burden | What is the current LDH? Marker of tumor burden and transformation. |
| 2 | clinical_pharmacist | Specialist review | Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication. |
Skills (recommended) — for consideration (1)
Data quality
Usable with caveats. No critical default-track gap was found, but the MDT should review the listed caveats before final sign-off.
- Biomarker coverage: 0/0 known (100%), 0 missing, 0 default-track gaps
- Unevaluated RedFlags: RF-AML-CD33-POS-GO-CANDIDATE, RF-AML-CORE-BINDING-FACTOR-FAVORABLE, RF-AML-EMERGENCY-TLS-LEUKOSTASIS, RF-AML-FLT3-ACTIONABLE, RF-AML-FRAILTY-AGE, RF-AML-HIGH-RISK-BIOLOGY, RF-AML-IDH1-MUT-ACTIONABLE, RF-AML-IDH2-MUT-ACTIONABLE, RF-AML-INFECTION-SCREENING, RF-AML-KMT2A-ACTIONABLE, RF-AML-MEASURABLE-RESIDUAL-DISEASE, RF-AML-NPM1-MUT-FAVORABLE, RF-AML-ORGAN-DYSFUNCTION, RF-AML-SECONDARY-AML-MRC-CPX351-ELIGIBLE, RF-AML-TP53-ADVERSE, RF-AML-TRANSFORMATION-PROGRESSION, RF-ANKRD26-CONFIRMED-CARRIER, RF-CASCADE-LFS-FDR-POSITIVE, RF-CEBPA-CONFIRMED-CARRIER, RF-DDX41-CONFIRMED-CARRIER, RF-ETV6-CONFIRMED-CARRIER, RF-IATROGENIC-ALKYLATOR-TAML-PREVENTION, RF-IATROGENIC-ANTHRACYCLINE-CARDIO-PREVENTION, RF-IATROGENIC-ANTHRACYCLINE-LATE-CARDIO-PREVENTION, RF-IATROGENIC-ASCT-SECONDARY-MDS-AML-PREVENTION, RF-IATROGENIC-PLATINUM-LATE-PREVENTION, RF-IATROGENIC-PRIOR-RADIATION-PREVENTION, RF-IATROGENIC-TOPO2-TAML-PREVENTION, RF-LI-FRAUMENI-CONFIRMED-CARRIER, RF-LI-FRAUMENI-FAMILY-HISTORY-SUSPICION, RF-LIFESTYLE-TOBACCO-CANCER-PREVENTION, RF-MPN-SECONDARY-LEUKEMIA-PREVENTION, RF-OCC-BENZENE-MALIGNANCY-PREVENTION, RF-OCC-FORMALDEHYDE-PREVENTION, RF-OCC-IONIZING-RADIATION-PREVENTION, RF-OCC-PAINTERS-PREVENTION, RF-RUNX1-CONFIRMED-CARRIER
Technical MDT skill metadata (1/16 activated in this plan)
All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).
| Specialist | skill_id | Version | Last reviewed | Sign-offs | Domain |
|---|
| Cellular therapy specialist (CAR-T) | cellular_therapy_specialist | v0.1.0 | 2026-04-25 | 0 | cellular_therapy |
| Clinical pharmacist | clinical_pharmacist | v0.1.0 | 2026-04-25 | 0 | clinical_pharmacy |
| Hematologist / oncohematologist | hematologist | v0.1.0 | 2026-04-25 | 0 | hematology_oncology |
| Hematopathologist (lymphoma / leukemia / myeloma) | hematopathologist | v0.1.0 | 2026-04-25 | 0 | hematopathology |
| Infectious disease / hepatology | infectious_disease_hepatology | v0.1.0 | 2026-04-25 | 0 | infectious_diseases |
| Medical oncologist (solid-tumor chemotherapist) | medical_oncologist | v0.1.0 | 2026-04-25 | 0 | solid_oncology |
| Molecular geneticist / molecular oncologist | molecular_geneticist | v0.1.0 | 2026-04-25 | 0 | molecular_oncology |
| Palliative care | palliative_care | v0.1.0 | 2026-04-25 | 0 | palliative_care |
| Pathologist (general) | pathologist | v0.1.0 | 2026-04-25 | 0 | pathology |
| Primary care / family physician | primary_care | v0.1.0 | 2026-04-25 | 0 | primary_care |
| Psycho-oncologist | psychologist | v0.1.0 | 2026-04-25 | 0 | psychosocial |
| Radiation oncologist | radiation_oncologist | v0.1.0 | 2026-04-25 | 0 | radiation_oncology |
| Radiologist | radiologist | v0.1.0 | 2026-04-25 | 0 | diagnostic_imaging |
| Social worker / case manager | social_worker_case_manager | v0.1.0 | 2026-04-25 | 0 | psychosocial |
| Surgical oncologist | surgical_oncologist | v0.1.0 | 2026-04-25 | 0 | surgical_oncology |
| Transplant specialist (BMT) | transplant_specialist | v0.1.0 | 2026-04-25 | 0 | cellular_therapy |
Sources cited
- SRC-ADMIRAL-PERL-2019: Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML (2019)
- SRC-ELN-AML-2022: Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel (2022)
- SRC-ESMO-AML-2020: Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2020)
- SRC-NCCN-AML-2025: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia (v.X.2025)
- SRC-VIALE-A-DINARDO-2020: Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia (2020)
Experimental options (clinical trials)
Third plan track — open-enrollment trials from ClinicalTrials.gov. Render-time metadata; engine selection is not affected by this block (CHARTER §8.3). Last synced: 2026-09-09.
| NCT | Title | Phase | Status | Sponsor | UA | Signals | Eligibility (excerpt) |
|---|
| NCT07514832 | VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial | PHASE2 | RECRUITING | — | Small N (<50) Surrogate endpoint only Single country | |
| NCT03300492 | Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS | PHASE1 / PHASE2 | RECRUITING | — | Small N (<50) Single country | |
| NCT06816134 | Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia | PHASE2 | RECRUITING | — | Small N (<50) Single country | |
| NCT06741722 | Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML | PHASE2 | RECRUITING | — | Small N (<50) Single country | |
| NCT07292272 | Halt Aging in Survivors of Blood Cancers | NA | RECRUITING | — | Single country | |
| NCT04678401 | IS-free Treg HaploHCT | PHASE1 | RECRUITING | — | Phase 1 only Small N (<50) Single country | |
| NCT06557421 | De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients | PHASE2 | RECRUITING | — | Surrogate endpoint only Single country | |
| NCT06191263 | Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML | PHASE2 | RECRUITING | — | — | |
| NCT06379360 | Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients | PHASE2 | RECRUITING | — | Single country | |
| NCT07250646 | A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis | PHASE1 | RECRUITING | — | Phase 1 only Small N (<50) Single country | |
Verify recruitment status directly with the trial site. ctgov data can lag behind current UA-site status.
Option availability in Ukraine
Per-track UA registration · NSZU · cost · access pathway. Render-time metadata; engine selection does not depend on these fields (CHARTER §8.3).
| Option | UA registration | NSZU | Cost orientation | Access pathway |
|---|
| Aggressive plan Revumenib monotherapy for R/R KMT2A-rearranged AML (REG-REVUMENIB-AML) 1/1 component drug(s) not registered in Ukraine +1 | ✗ not registered | ✗ out-of-pocket | ₴-? — verify pathway | not recorded |
| Aggressive plan Gilteritinib monotherapy for R/R FLT3-mutated AML (REG-GILTERITINIB-AML) 1/1 component drug(s) not registered in Ukraine +1 | ✗ not registered | ✗ out-of-pocket | ₴-? — verify pathway | not recorded |
| Aggressive plan Enasidenib monotherapy for R/R IDH2-mutated AML (REG-ENASIDENIB-AML) 1/1 component drug(s) not registered in Ukraine +1 | ✗ not registered | ✗ out-of-pocket | ₴-? — verify pathway | not recorded |
| Standard plan Venetoclax + Azacitidine (AML, unfit) — VIALE-A schedule (REG-VEN-AZA-AML) | ✓ registered | ✓ covered | ₴-? — verify pathway | NSZU formulary |
| Trial · NCT07514832 VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT03300492 Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06816134 Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06741722 Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT07292272 Halt Aging in Survivors of Blood Cancers No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT04678401 IS-free Treg HaploHCT No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06557421 De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06191263 Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06379360 Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT07250646 A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
Cost information is orientation. Verify with a specific pharmacy / foundation / trial site. Status updated: 2026-09-09.